HK1089690A1 - Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application - Google Patents

Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application

Info

Publication number
HK1089690A1
HK1089690A1 HK06111151.6A HK06111151A HK1089690A1 HK 1089690 A1 HK1089690 A1 HK 1089690A1 HK 06111151 A HK06111151 A HK 06111151A HK 1089690 A1 HK1089690 A1 HK 1089690A1
Authority
HK
Hong Kong
Prior art keywords
duration
activity
action
alkyl
topical
Prior art date
Application number
HK06111151.6A
Other languages
English (en)
Inventor
Nicholas S Bodor
Original Assignee
Nicholas S Bodor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas S Bodor filed Critical Nicholas S Bodor
Publication of HK1089690A1 publication Critical patent/HK1089690A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
HK06111151.6A 2003-06-19 2006-10-11 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application HK1089690A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47949603P 2003-06-19 2003-06-19
PCT/US2004/019367 WO2005000317A1 (en) 2003-06-19 2004-06-17 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application

Publications (1)

Publication Number Publication Date
HK1089690A1 true HK1089690A1 (en) 2006-12-08

Family

ID=33551891

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06111151.6A HK1089690A1 (en) 2003-06-19 2006-10-11 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application

Country Status (12)

Country Link
US (2) US7560448B2 (es)
EP (1) EP1653974B1 (es)
JP (1) JP4893305B2 (es)
KR (1) KR20060032596A (es)
CN (1) CN1838960A (es)
AT (1) ATE454154T1 (es)
CA (1) CA2558944C (es)
DE (1) DE602004025002D1 (es)
ES (1) ES2339351T3 (es)
HK (1) HK1089690A1 (es)
MX (1) MXPA05013898A (es)
WO (1) WO2005000317A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
US20070110812A1 (en) * 2005-11-14 2007-05-17 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
GB0523251D0 (en) * 2005-11-15 2005-12-21 Glaxo Group Ltd Novel compounds
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
MX2009009213A (es) * 2007-03-01 2010-03-15 Univ America Catholic Bacteriofago t4 unido a un substrato.
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2373693A4 (en) * 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
DK3064217T3 (en) 2009-01-06 2018-05-28 Galenagen Llc COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
ES2726978T3 (es) 2011-04-21 2019-10-11 Curemark Llc Compuestos para el tratamiento de trastornos neuropsiquiátricos
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2022225999A1 (en) * 2021-04-19 2022-10-27 Bodor Laboratories, Inc. Lung-targeted corticosteroid treatment in viral respiratory disease, covid-19 and ards (acute respiratory distress syndrome)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
US3828080A (en) 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
CH628355A5 (de) 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
ZA814440B (en) * 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4496335A (en) * 1982-12-13 1985-01-29 Dayco Corporation Pulley construction and method of making the same
US5981517A (en) 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
TW503113B (en) * 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
AU2001245273A1 (en) * 2000-02-15 2001-08-27 Board Of Trustees Of The University Of Arkansas Recombinant vector expressing a beta2-adrenergic receptor and use in treating airway and vascular diseases

Also Published As

Publication number Publication date
EP1653974A1 (en) 2006-05-10
EP1653974B1 (en) 2010-01-06
US20090239833A1 (en) 2009-09-24
ES2339351T3 (es) 2010-05-19
ATE454154T1 (de) 2010-01-15
US20050026892A1 (en) 2005-02-03
DE602004025002D1 (de) 2010-02-25
JP2007520437A (ja) 2007-07-26
KR20060032596A (ko) 2006-04-17
US7923441B2 (en) 2011-04-12
US7560448B2 (en) 2009-07-14
WO2005000317A1 (en) 2005-01-06
CN1838960A (zh) 2006-09-27
CA2558944A1 (en) 2005-01-06
JP4893305B2 (ja) 2012-03-07
CA2558944C (en) 2012-05-29
MXPA05013898A (es) 2006-05-25

Similar Documents

Publication Publication Date Title
HK1089690A1 (en) Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application
HK1089691A1 (en) Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TW200603813A (en) Cyclic progestin regimens and kits
NZ524104A (en) Exemestane as chemopreventing agent
BRPI0518695A2 (pt) uso de uma liga de cobre-zinco
HK1043942A1 (en) Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
WO2001054654A3 (en) Reduction of hair growth
GB0105772D0 (en) Use
GB2429883A (en) Extendable voice commands
ATE488847T1 (de) Kontaktelement
ATE410171T1 (de) Graduierte östrogen-kontrazeptiva
GB2414183A (en) Methods and devices for therapeutic treatment cardiac and other pathologies
ATE411353T1 (de) Silikonzusammensetzung, die durch hydrosilylierung in gegenwart eines carben-metall-katalysators vernetzt werden kann und katalysator
DE60019121D1 (de) Kaliumkanäleöffner
ATE492282T1 (de) Zusammensetzung aus steroiden mit transporterweiterter corticosteroid-aktivität
HK1088028A1 (en) Use of metal alkanedithiols as crosslkinking agents for unsaturated rubbers
TW200732286A (en) Ester compound and its use
MXPA04007362A (es) Reduccion del crecimiento de vello.
TW200514547A (en) Low irritant adhesive dressing
DE602004018921D1 (de) D dienogest
WO2003104254A3 (en) NOVEL ANDROSTANE AND ANDROSTENE DERIVATIVES WITH ASCORBIC ACID AND THEIR USE IN THE TREATMENT OR PREVENTION OF DIFFERENT CONDITIONS, DISEASES AND DISORDERS
RS101004A (en) Use of new etonogestrel esters
HK1099026A1 (en) Synthesis of spongosine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230621